alexa Nanopharmaceutics Innovations in Gene Therapy: Moving Towards Non-Viral and Non-Invasive Delivery Methods | Open Access Journals
ISSN: 2155-983X
Journal of Nanomedicine & Biotherapeutic Discovery
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Nanopharmaceutics Innovations in Gene Therapy: Moving Towards Non-Viral and Non-Invasive Delivery Methods

M. Foldvari*

School of Pharmacy and Waterloo Institute of Nanotechnology, University of Waterloo, Canada

*Corresponding Author:
M. Foldvari
School of Pharmacy and Waterloo Institute of Nanotechnology
University of Waterloo, Canada
Tel: 519-888-4567-21306
E-mail: [email protected]

Received Date: July 25, 2014; Accepted Date: July 28, 2014; Published Date: July 30, 2014

Citation: Foldvari M (2014) Nanopharmaceutics Innovations in Gene Therapy: Moving Towards Non-Viral and Non-Invasive Delivery Methods. J Nanomedine Biotherapeutic Discov 4: e135. doi: 10.4172/2155-983X.1000e135

Copyright: © 2014 Foldvari M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Nanomedicine & Biotherapeutic Discovery

Gene therapy, the targeted insertion of DNA coding for a therapeutic gene into the nuclei of diseased cells or tissues followed by its expression, is one of the most promising new therapies for a host of diseases and conditions [1]. The first gene therapy product, Gendicine (adenoviral vector-based) was approved in China in 2003 for head and neck cancer. On July 24, 2012 the European Medicines Agency approved the adeno-associated viral (AAV) gene therapy, Glybera by uniQure, for lipoprotein lipase deficiency, an orphan disease. Recent progress towards patient use indicates that there is still more work ahead for developing approved products for other indications. More than 1,800 gene therapy clinical trials have been carried out in the past 25 years, including the currently in-progress of about 400 studies [2].

As recent reports of encouraging progress are emerging with viral vector-based therapies, the field is developing more confidence in gene therapy applications. For example, uniQure is developing the GDNF (glial cell derived neurotrophic factor) gene in their AAV-2 delivery vector using a bilateral, convection-enhanced delivery to the putamen (NCT01621581) and Oxford Biomedica reported Phase 1/2 clinical trial results with ProSavin an intrastriatally delivered a tricistronic lentiviral vector-based vector encoding tyrosine hydroxylase, L-amino acid decarboxylase (AADC), and cyclohydrolase 1 gene therapy, both aimed at restoring dopamine production in patients with advanced Parkinson’s disease [3]. MYDICAR®, an AAV-based sarcoplasmic reticulum calcium ATPase (SERCA2a) gene therapy, being developed by Celladon to restore SERCA2a enzyme levels, is currently in clinical trials for evaluating its efficacy in improving left ventricular function and remodeling in NYHA class III or IV chronic heart failure patients is administered as a single intracoronary infusion [4]. This study received ‘breakthrough therapy designation’ from U.S. Food and Drug Administration (FDA) through the FDA Safety and Innovation Act of 2012 (FDASIA) to expedite drug development and review of innovative new medicines that address certain unmet medical needs for serious or life-threatening diseases or conditions.

In spite of the tremendous progress, a future challenges in gene therapy treatments include the development of gene delivery vectors with targeting ability, controllable, high and prolonged transfection efficiency, improved safety and less complicated or non-invasive administration methods. Novel non-viral delivery systems represent options for gene therapy that could fulfill these mentioned requirements. However, non-viral systems are not yet effective and specific enough for clinical applications and improvements in both the structure and function of these systems are required. Non-viral gene delivery vectors are an extensive class of man-made complexes or nanoparticles (NPs) composed of a nucleic acid cargo, typically a plasmid, with one or more soft matters such as cationic lipids (DOTAP, DOTMA), surfactants, biologicals (gelatin, chitosan), metals (gold, magnetic iron) and synthetic polymers (PLG, PEI, PAMAM). This engineering flexibility provides several key advantages over viral delivery vectors, principally reduced immunogenicity resulting from their biologically inert material composition and reduced production costs. Moreover, this “bottom-up” design allows researchers to customize their composition and incorporate specific moieties to suit a wide range of applications.

Development of nano-sized delivery systems requires the understanding of a comprehensive set of parameters and the construction of fine-tuned particles capable of significantly more “intelligent” functions compared to traditional dosage forms. Among the many important properties, morphology and internal structure of nanoparticles play a significant role in their functional performance. At the cellular level, a multitude of parameters are of interest for fine-tuned customization. Important considerations in individual nanoparticle design for enhanced cellular interaction and drug delivery are size, surface charge, surface area, shape, surface coatings, stability and structure of particles. An interesting consideration in NP design is the size and shape of particles. Smaller particles less than 150 nm are typically taken up to a greater extent into cells, which has been shown for NPs made from various biomaterials. Until recently, all delivery systems studied were mostly spherical. The structure of lipoplexes has been the focus of both theoretical and experimental studies that examine the relationship between the morphological characteristics of lipoplexes and their functional activity. These various structural forms have been revealed in numerous studies using diffraction or magnetic resonance methods; however, the lack of understanding of the relationship between transfection and the nature of complexes has also necessitated determining other physical characteristics using various methods. A non-spherical particle shape (filament, ellipsoid, cube, rod, triangle, pentagon, disc) may provide significantly improved interactions with cells [5-10]. The relationship between the structure of DNA complexes and gene delivery has been of considerable interest in the past few years from both theoretical and experimental standpoint. The importance of the thorough understanding of particle properties is widely recognized [11,12], however, in practice there is still much to be done to fully detail out all relevant characteristics of old and new systems. NP biocompatibility, including pharmacokinetics of absorption, targetability, clearance and toxicity, is the direct result of the sum of the physicochemical features carefully designed under established dosage form design and newly developing nanopharmaceutics principles.

For selected applications, the route of administration can be needle-free [13-16], although in most cases gene delivery systems are administered by injection. In the next few years new technologies will allow non-invasive administration methods, especially into the skin, eye, and mucus membranes, which will provide more effective treatment modalities, patient acceptance and potentially self-administration.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 11521
  • [From(publication date):
    August-2014 - Sep 20, 2017]
  • Breakdown by view type
  • HTML page views : 7760
  • PDF downloads :3761
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materials[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords